Bio-Techne Corporation vs CRISPR Therapeutics AG: SG&A Expense Trends

SG&A Expense Trends in Biotech: A Comparative Analysis

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and industry enthusiasts. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Bio-Techne Corporation and CRISPR Therapeutics AG, from 2014 to 2023.

Bio-Techne Corporation has shown a consistent upward trajectory in SG&A expenses, with a remarkable 550% increase over the decade, peaking at nearly $400 million in 2023. This growth reflects the company's expanding operations and strategic investments in innovation.

Conversely, CRISPR Therapeutics AG, a pioneer in gene-editing technology, experienced a more volatile trend. Their SG&A expenses surged by over 1,900% from 2014 to 2021, reaching a high of approximately $102 million. However, a decline in 2023 suggests a strategic shift or cost optimization efforts.

This comparative analysis highlights the contrasting financial strategies of these biotech giants, offering valuable insights into their operational priorities.